Key Developments: Zeltia SA (ZEL.MC)

ZEL.MC on Madrid SE C.A.T.S.

1.58EUR
17 May 2013
Price Change (% chg)

€-0.01 (-0.94%)
Prev Close
€1.59
Open
€1.59
Day's High
€1.61
Day's Low
€1.56
Volume
222,410
Avg. Vol
354,003
52-wk High
€1.66
52-wk Low
€1.02

Search Stocks

Latest Key Developments (Source: Significant Developments)

Zeltia SA’s PharmaMar Completes Phase Ib Study Of PM01183 In Combination With Doxorubicin
Tuesday, 14 May 2013 02:22am EDT 

Zeltia SA announced that its subsidiary, PharmaMar, has completed Phase Ib Study of PM01183 in combination with doxorubicin. The combination has shown antitumor activity in all cancer types included. The results of this study will be presented at an upcoming oncology meeting.  Full Article

Zeltia SA’s Sylentis Commences Phase Two Clinical Trials With SYL1001 For Treating Eye Discomfort
Wednesday, 27 Feb 2013 11:50am EST 

Zeltia SA announced that its subsidiary Sylentis has commenced a Phase Two clinical trial with SYL1001 for treating or preventing eye discomfort. The endpoint of this Phase Two trial is to determine the analgesic effect of SYL1001 in patients with dry eye and eye discomfort. This is Sylentis's fifth clinical trial using products based on RNAi technology and its second compound to undergo clinical trials, evidencing the Company's commitment to developing compounds to treat eye diseases. This Phase II trial with SYL1001 will be conducted at Hospital Clinico San Carlos (Madrid), Instituto Oftalmologico Fernandez-Vega (Oviedo) and Fundacion Jimenez Diaz (Madrid).  Full Article

Zeltia SA announces Further Details On Agreement Between Its Pharma Mar SA And Janssen Pharmaceutical Companies' Janssen Products LP
Monday, 4 Feb 2013 02:48am EST 

Zeltia SA announced that, regarding announcement on December 27, 2011, its subsidiary, Pharma Mar SA (PharmaMar) has received from Janssen Pharmaceutical Companies' Janssen Products LP the third payment of USD 25 million for reached milestones based on the development of Yondelis.  Full Article

Zeltia SA's GENOMICA SAU Establishes Subsidiary
Tuesday, 22 Jan 2013 02:17am EST 

Zeltia SA announced that its subsidiary GENOMICA SAU goes a step further in its internationalization process by establishing, as of January 17, 2013, new Scandinavian subsidiary GENOMICA AB. Based in Lund (Sweden), GENOMICA AB intends to support the Scandinavian market (Denmark, Sweden and Norway), due to its strategic importance and also for its high growth potential.  Full Article

Zeltia SA's Subsidiary Noscira SA To Be Dissolved
Tuesday, 18 Dec 2012 02:06pm EST 

Zeltia SA announced that on December 18, 2012, during the Extraordinary Shareholders’ Meeting of its 73.32%-owned subsidiary Noscira SA it was agreed to dissolve the company, starting the liquidation period. Further details were not disclosed.  Full Article

Zeltia SA’s PharmaMar’s Aplidin Phase 3 ADMYRE Trial In Relapsed Refractory Multiple Myeloma Achieves Initial Target Response Rate
Tuesday, 18 Dec 2012 02:22am EST 

Zeltia SA announced that the Independent Data Monitoring Committee (IDMC) has notified PharmaMar, a biopharmaceutical subsidiary of the Company, that it recommends completion of the on-going Phase 3 trial of Aplidin in patients with relapsed/refractory multiple myeloma. The two-stage, 2:1 randomized Phase 3 study is evaluating Aplidin in combination with dexamethasone versus dexamethasone alone. The IDMC recommendation follows an analysis of efficacy and safety data from the 60 patients required in the first stage of the Phase 3 trial in which the study met the established efficacy threshold.  Full Article

Zeltia SA’s Pharma Mar Receives 14 New Marketing Authorizations For Yondelis In 10 Countries-Reuters
Monday, 3 Dec 2012 02:55am EST 

Reuters reported that the regulatory authorities in 10 countries have granted 14 new marketing authorizations for anticancer Pharma Mar’s (Zeltia SA’s subsidiary) Yondelis. 10 of these marketing authorizations have been received in Bahrain, Costa Rica, Dominican Republic, Jamaica, Jordan, Nepal, Oman, Panama, Qatar and Vietnam for Yondelis in combination with Caelyx to treat a type of recurrent ovarian cancer. The other four marketing authorizations have been obtained in Bahrain, Dominican Republic, Jordan and Nepal for Yondelis to treat soft tissue sarcoma (STS).  Full Article

Zeltia SA’s Subsidiary Starts Commercial Activity in Germany
Wednesday, 7 Nov 2012 02:25am EST 

Zeltia SA announced that on November 6, 2012, the subsidiary PharmaMar SA of the Company’s subsidiary PharmaMar AG has started its commercial activity in Germany.  Full Article

Zeltia SA’s Subsidiary, Noscira SA, To Propose Dissolution
Tuesday, 6 Nov 2012 02:00pm EST 

Zeltia SA announced that its subsidiary, Noscira SA, has decided to hold the Extraordinary Shareholders’ Meeting on December 18, 2012 or December 19, 2012 and propose a dissolution of Noscira SA due to the deterioration of the company’s investment.  Full Article

Zeltia SA Announces Negative Results From Phase II Trial Of Alzheimer Treatment-Reuters
Thursday, 11 Oct 2012 02:23am EDT 

Reuters reported that Zeltia SA’s Phase II trial of a drug for the treatment of Alzheimer did not achieve the intended objectives. The study evaluated the efficacy of Noscira’s drug tideglusib, versus placebo plus standard treatment in patients with mild-stage of Alzheimer.  Full Article

Zeltia SA News

» More ZEL.MC News

Earnings vs. Estimates

» More Financials
Search Stocks